| scholarly article | Q13442814 |
| P2093 | author name string | Prasad S Kulkarni | |
| Simonetta Viviani | |||
| Elisa Marchetti | |||
| Marie-Pierre Preziosi | |||
| Julie Chaumont | |||
| Lionel Martellet | |||
| Marie-Françoise Makadi | |||
| Véronique Mazarin-Diop | |||
| P2860 | cites work | Regulatory oversight of clinical trials in Africa: progress over the past 5 years | Q84549626 |
| Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution | Q34017750 | ||
| Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine | Q34191003 | ||
| Epidemic meningitis, meningococcaemia, and Neisseria meningitidis | Q34644525 | ||
| Meningococcal carriage in the African meningitis belt | Q37018218 | ||
| Joint reviews and inspections: strategic forms of collaboration for strengthening the regulatory oversight of vaccine clinical trials in Africa | Q37615610 | ||
| Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience | Q38011315 | ||
| Manson Lecture. Meningococcal meningitis in Africa | Q48580950 | ||
| Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. | Q50919180 | ||
| Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. | Q51004314 | ||
| The Meningitis Vaccine Project | Q80374870 | ||
| Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults | Q80390726 | ||
| P433 | issue | 48 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meningitis | Q48143 |
| Sub-Saharan Africa | Q132959 | ||
| lessons learned | Q1673259 | ||
| P304 | page(s) | 6859-6863 | |
| P577 | publication date | 2012-09-16 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Conducting vaccine clinical trials in sub-Saharan Africa: operational challenges and lessons learned from the Meningitis Vaccine Project | |
| P478 | volume | 30 |
| Q36310614 | "You can save time if…"-A qualitative study on internal factors slowing down clinical trials in Sub-Saharan Africa |
| Q64120072 | Accelerating Typhoid Conjugate Vaccine Introduction: What Can Be Learned From Prior New Vaccine Introduction Initiatives? |
| Q28598111 | Ambiguous Capture: Collaborative Capitalism and the Meningitis Vaccine Project |
| Q36265032 | Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years |
| Q42733082 | Challenges and impact of conducting vaccine trials in Asia and Africa: New Technologies in Emerging Markets, October 16th-18th 2012; World Vaccine Congress, Lyon |
| Q52607696 | Challenges in conducting a community-based influenza vaccine trial in a rural community in northern India. |
| Q37086545 | Design-driven, multi-use research agendas to enable applied synthetic biology for global health |
| Q26778270 | Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine |
| Q30378952 | Health research capacity development in low and middle income countries: reality or rhetoric? A systematic meta-narrative review of the qualitative literature. |
| Q57092771 | Implementing a Multisite Clinical Trial in the Midst of an Ebola Outbreak: Lessons Learned From the Sierra Leone Trial to Introduce a Vaccine Against Ebola |
| Q53711068 | Increasing protocol suitability for clinical trials in sub-Saharan Africa: a mixed methods study. |
| Q64120046 | Logistics of Implementing a Large-scale Typhoid Vaccine Trial in Kathmandu, Nepal |
| Q34452176 | Perinatal distress in women in low- and middle-income countries: allostatic load as a framework to examine the effect of perinatal distress on preterm birth and infant health |